June 25th 2025
Marketed as Orlynvah, oral sulopenem from Iterum Therapeutics was FDA approved last fall for uncomplicated urinary tract infections (uUTIs), and has shown efficacy against infections caused by Escherichia coli, Klebsiella pneumoniae, and Proteus mirabilis.
Cases and Conversations™: Applying Best Practices to Prevent Shingles in Your Practice
View More
Fighting Disparities and Saving Lives: An Exploration of Challenges and Solutions in Cancer Care
View More
Advances in™ Atopic Dermatitis: Addressing Unmet Needs in Patients With Skin of Color
View More
A Shield of Protection: Unmet Needs in COVID-19 Prevention and Control
October 7, 2025
Register Now!
Tackling Inequities in IBD: Inclusive Solutions for Elevated Patient Care
View More
Addressing Racial Disparities in Multiple Myeloma: Forging a Path Towards Health Equity in Clinical Trials and Everyday Practice
View More
Funding Isn’t Everything: Bringing Pharma to the Table for the Pasteur Act
October 8th 2024The pharmaceutical industry faces challenges when investing in new antibiotics, which emphasizes the need for regulatory reforms, incentives, and collaborative efforts between government, healthcare organizations, and private companies. The prospective bill, the Pasteur Act, is one potential strategy to help in these areas, and incentivize pharmaceutical companies to develop these essential therapies.
Read More
GigaGen's New Contract with BARDA for Polyclonal Antibody Development
October 4th 2024Carter Keller discusses the company's recent $135.2 million contract with BARDA to develop recombinant polyclonal antibody therapies targeting botulinum neurotoxins and an unspecified biothreat, highlighting their innovative approach to address emerging health threats.
Watch
Long-Acting Lipoglycopeptides for the Treatment of Severe Infections
September 19th 2024Long-acting lipoglycopeptides (LGPs) like dalbavancin, oritavancin, and telavancin were developed with extended half-lives, initially targeting acute bacterial skin and skin structure infections (ABSSSIs). However, recent studies have explored their potential in treating other infections, including infective endocarditis (IE), bone and joint infections (BJIs), and bloodstream infections (BSIs), offering an alternative to standard care and outpatient antimicrobial therapy.
Read More
BWC0977 Presents a New Approach to Addressing Antimicrobial Resistance
September 19th 2024Initial studies show its effectiveness against various bacteria, including those resistant to standard treatments, and it is being developed in both intravenous and oral forms to improve patient access.
Read More
Honoring Her Daughter’s Legacy After a Long-Standing Battle With Antimicrobial Resistance
September 5th 2024After Diane Shader Smith lost her daughter, Mallory, to a multidrug resistant infection, she turned her personal tragedy into a mission designed to inform people about antimicrobial resistance (AMR), and have the public coalesce around this expanding medical issue.
Watch